Literature DB >> 27271552

Update on the role of molecular factors and fibroblasts in the pathogenesis of Dupuytren's disease.

Massimiliano Tripoli1, Adriana Cordova2, Francesco Moschella2.   

Abstract

The mechanism by which the fibroblast is able to trigger palmar fibromatosis is still not yet fully understood. It would appear certain that the "abnormal" fibroblasts continuously synthesise profibrotic cytokines which are able to determine the activation to myofibroblasts, to stimulate them to the further proliferation and synthesis of other cytokines, to modify the cells' differentiation and ultrastructural characteristics, as well as the production of matrix and other proteins. Several fibroblast growth factors have been suggested to be responsible of an abnormal cell activation with an aberrantly elevated collagen synthesis and extracellular deposition in Dupuytren's disease, as TGF-Beta, TNF-Alfa, PDGF, GM-CSF, free radicals, metalloproteinases, sex hormones, gene modified expression, mechanical stimulation. The Authors review the current state of knowledge in the field, by analyzing the role of these cytokines in the palmar fibromatosis.

Entities:  

Keywords:  Cytokines; Dupuytren’s disease; Fibroblast

Year:  2016        PMID: 27271552      PMCID: PMC5143316          DOI: 10.1007/s12079-016-0331-0

Source DB:  PubMed          Journal:  J Cell Commun Signal        ISSN: 1873-9601            Impact factor:   5.782


  99 in total

1.  Post-transcriptional regulation of alpha-smooth muscle actin determines the contractile phenotype of Dupuytren's nodular cells.

Authors:  Liaquat Suleman Verjee; Kim Midwood; Dominique Davidson; Mark Eastwood; Jagdeep Nanchahal
Journal:  J Cell Physiol       Date:  2010-09       Impact factor: 6.384

2.  Unraveling the signaling pathways promoting fibrosis in Dupuytren's disease reveals TNF as a therapeutic target.

Authors:  Liaquat S Verjee; Jennifer S N Verhoekx; James K K Chan; Thomas Krausgruber; Vicky Nicolaidou; David Izadi; Dominique Davidson; Marc Feldmann; Kim S Midwood; Jagdeep Nanchahal
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-19       Impact factor: 11.205

3.  Potential treatment for clubfeet based on growth factor blockade.

Authors:  C Li; Q Nguyen; W G Cole; B A Alman
Journal:  J Pediatr Orthop       Date:  2001 May-Jun       Impact factor: 2.324

4.  Injectable collagenase Clostridium histolyticum: a new nonsurgical treatment for Dupuytren's disease.

Authors:  David Gilpin; Stephen Coleman; Stephen Hall; Anthony Houston; Jeff Karrasch; Nigel Jones
Journal:  J Hand Surg Am       Date:  2010-12       Impact factor: 2.230

5.  Biochemical changes in the collagen of the palmar fascia in patients with Dupuytren's disease.

Authors:  D Brickley-Parsons; M J Glimcher; R J Smith; R Albin; J P Adams
Journal:  J Bone Joint Surg Am       Date:  1981-06       Impact factor: 5.284

6.  Differential gene expression analysis of subcutaneous fat, fascia, and skin overlying a Dupuytren's disease nodule in comparison to control tissue.

Authors:  Barbara Shih; Jason J Brown; Daniel J Armstrong; Tommy Lindau; Ardeshir Bayat
Journal:  Hand (N Y)       Date:  2009-01-29

7.  Dupuytren's contracture. An electron microscopic, biochemical, and clinical correlative study.

Authors:  R H Gelberman; D Amiel; R M Rudolph; R M Vance
Journal:  J Bone Joint Surg Am       Date:  1980-04       Impact factor: 5.284

8.  Wound healing-associated proteins Hsp47 and fibronectin are elevated in Dupuytren's contracture.

Authors:  Jeffrey C Howard; Vincenzo M Varallo; Douglas C Ross; Kenneth J Faber; James H Roth; Shannon Seney; Bing Siang Gan
Journal:  J Surg Res       Date:  2004-04       Impact factor: 2.192

9.  Fibroblasts from phenotypically normal palmar fascia exhibit molecular profiles highly similar to fibroblasts from active disease in Dupuytren's Contracture.

Authors:  Latha Satish; William A LaFramboise; Sandra Johnson; Linda Vi; Anna Njarlangattil; Christina Raykha; John Michael Krill-Burger; Phillip H Gallo; David B O'Gorman; Bing Siang Gan; Mark E Baratz; Garth D Ehrlich; Sandeep Kathju
Journal:  BMC Med Genomics       Date:  2012-05-04       Impact factor: 3.063

10.  Laminin-rich blood vessels display activated growth factor signaling and act as the proliferation centers in Dupuytren's contracture.

Authors:  Janeli Viil; Katre Maasalu; Kristina Mäemets-Allas; Liis Tamming; Kadi Lõhmussaar; Mikk Tooming; Sulev Ingerpuu; Aare Märtson; Viljar Jaks
Journal:  Arthritis Res Ther       Date:  2015-05-28       Impact factor: 5.156

View more
  3 in total

1.  The Role of Functional Polymorphisms in the Extracellular Matrix Modulation-Related Genes on Dupuytren's Contracture.

Authors:  Gediminas Samulenas; Ruta Insodaite; Edita Kunceviciene; Roberta Poceviciute; Lorena Masionyte; Urte Zitkeviciute; Loreta Pilipaityte; Alina Smalinskiene
Journal:  Genes (Basel)       Date:  2022-04-23       Impact factor: 4.141

2.  Dupuytren's and Ledderhose Diseases in a Family with LMNA-Related Cardiomyopathy and a Novel Variant in the ASTE1 Gene.

Authors:  Michael V Zaragoza; Cecilia H H Nguyen; Halida P Widyastuti; Linda A McCarthy; Anna Grosberg
Journal:  Cells       Date:  2017-11-01       Impact factor: 6.600

3.  Evaluation of WNT Signaling Pathway Gene Variants WNT7B rs6519955, SFRP4 rs17171229 and RSPO2 rs611744 in Patients with Dupuytren's Contracture.

Authors:  Gediminas Samulėnas; Alina Smalinskienė; Rytis Rimdeika; Kęstutis Braziulis; Mantas Fomkinas; Rokas Paškevičius
Journal:  Genes (Basel)       Date:  2021-08-24       Impact factor: 4.096

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.